Company Overview and News
HALIFAX, Nova Scotia, June 08, 2018 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD) ("Erdene" or "Company") is pleased to announce that it has closed its non-brokered private placement ("Private Placement") announced on May 31, 2018 for proceeds of $4.12 million.
SAND SSL SDDXF SNXZF TCKRF ERDCF ERD TECK
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
HRT MGG HRTFF MMRGF GFI.WI FNV NEM NMKEF RSG PRB RNX RNKLF KGC NMX RMGGF FQVLF AEM MACIF AG FQM GFIOF NDM WPM RPM FR SAND FNV.WT.A SSL GPL SDDXF ALO PROBF K RPMGD WHGOF RPMGF SNXZF ORG RGLD RNX.WT RMGGY GFI PGLC CANWF FNV RGL
Here's a monthly recap of the top news in the gold mining sector, including acquisitions and takeover announcements, financial results and other relevant updates, to keep readers up-to-date on news in the sector. Here's my last update for April if you missed it.
ARCTF LUNMF NSRPF NEM YRI KGI.DB CG LUNCF MAX TMMFF NXXGD NSU CAGDF RSG AMI NXXGF AUY EDVVF RMGGF MDRPF IAG KL ABX EDV SAND SSL ABX SDDXF KGI NXS KGI.DB.A EDVMF NVO SNXZF ORG LUN TMR RMGGY EVR CANWF
Chicago, IL – May 31, 2018 – Today, Zacks Equity Research discusses Health Insurance, including Franco-Nevada Corp. (FNV - Free Report) , Sandstorm Gold Ltd. (SAND - Free Report) , IAMGOLD Corp. (IAG - Free Report) and Kinross Gold Corp. (KGC - Free Report) .
SAND SSL SDDXF TXN MATW K SNXZF ALIMR IMMR KGC DG XOXO XOMA IAG FNV
HALIFAX, Nova Scotia, May 31, 2018 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD) ("Erdene" or "Company") is pleased to announce that it has received approval from the Financial Regulatory Commission of Mongolia for a secondary listing of its common shares on the Mongolian Stock Exchange (“MSE”) and today has launched an offering of common shares to Mongolian residents (“Mongolia Offering”) as well as a concurrent non-brokered private placement ("Private Placement"), which in combination are expected to raise up to $4.
SAND SSL SDDXF SNXZF TCKRF ERDCF ERD TECK
In the current unstable financial climate, the need to reduce one’s susceptibility against changing economic fortunes has become a top priority for investors. This is where the safe-haven appeal of gold becomes alluring and often acts as a cushion to fall back on. In contrast to more volatile stock market investments, gold has always been valued as a solid and dependable means to protect wealth.
WFC WFCNP WFC.WS SAND SSL SDDXF WFC.PRL K WFC.PRJ SNXZF WFC.PRT WFC.PRR WFC.PRQ WFC.PRP KGC WFC.PRO WFC.PRN WFC.PRY WFC.PRX IAG WFC.PRW FNV WFC.PRV
Chicago, IL – May 30, 2018 – Today, Zacks Equity Research discusses Health Insurance, including Franco-Nevada Corp. (FNV - Free Report) , Sandstorm Gold Ltd. (SAND - Free Report) , IAMGOLD Corp. (IAG - Free Report) and Kinross Gold Corp. (KGC - Free Report) .
HD SAND SSL SDDXF TXN K SNXZF KGC GM.WS.A GM.WS.B GM.WS.C GM GM.WSB IAG FNV
Per the data available from the World Gold Council, global demand for gold declined 7% year over year to 973.5 tons in the first quarter of 2018 — the weakest first quarter in 10 years. The weak performance can primarily be attributed to a fall in investment demand for gold bars and gold-backed ETFs, partly due to range-bound gold prices. Let’s delve deeper and analyze the factors that led to the decline and also find out what is in store for the yellow metal.
HMY SAND SSL SDDXF PVG K SNXZF NG PVG KGC PGLC IAG HGMCF FNV
VANCOUVER, British Columbia, May 28, 2018 (GLOBE NEWSWIRE) -- Aton Resources Inc. (TSXV:AAN) (“Aton” or the “Corporation") is pleased to announce that it has closed its non-brokered private placement of 43,493,858 units for proceeds of $1,957,223.61 (the “Private Placement”). Sandstorm Gold Ltd. (“Sandstorm”) acquired 40,000,000 units in the Private Placement for proceeds of $1,800,000. Additionally, Sandstorm paid Aton $300,000 for a 1% Net Smelter Royalty over the Abu Marawat Concession Area (see news release dated May 9, 2018).
SAND SSL SDDXF SNXZF
NEW YORK, May 15 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 12.20 points, or 0.08 percent, to 16,097.81. * The biggest contributor to the TSX gain was Canadian National Railway Co, with 10.1 net index points. Industrials were the top sector contributor with 13 net points. * Leading the index were Element Fleet Management Corp, up 12.1 percent, Aphria Inc, up 7.5 percent, and Boyd Group Income Fund, higher by 4.
SAND SSL SDDXF YRI ACBFF SNXZF ACB APH AUY BFGIF BDRPF APHQF BYD.UN SEMFF
Royalty and streaming mining companies (RING)(SIL) have business models that are considered quite conservative because they don’t own mines. These companies have somewhat fixed income streams after making upfront payments for production rights to mines. This could be why this group of miners has seen higher valuation multiples than miners in other categories.
WPM RGLD SAND SSL SLW SDDXF SNXZF SLW RGL
Good morning. My name is Chris, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sandstorm Gold conference call. All lines have been placed on mute to prevent any background noise.
SAND SSL RIO SDDXF RIO MUX EDVMF SNXZF RTPPF MUX.RTWI RIO EDVVF RTNTF EVR MUX EDV
20h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...